Slideshow of doctors

GORE® VIABAHN® Device family

Join the next generation of care in the treatment of aortoiliac occlusive disease

Covered stents: Key advantages for complex lesions

Covered stents help address the shortcomings of bare metal stents1-3 in treating complex aortoiliac occlusive disease (AIOD) by:

  • Excluding plaque.
  • Preventing in-stent neointimal hyperplasia.2-4
  • Decreasing the risk of complications caused by distal embolization, perforation, rupture and dissection.5,6
  • Covering and sealing off vessel ruptures.
  • Promoting hemodynamic flow via a new flow lumen.

Covered stent grafts have shown excellent outcomes for treating complex AIOD

Covered stent grafts

Higher patency rates with covered stents

Comparative studies demonstrate a significant patency advantage versus bare metal1

Higher patency out to 3 years for TASC II D lesions:1

Kaplan Meier Curve

Covered stents are providing higher midterm patency rates compared to bare metal stents for:

    TASC D lesions Iliac occlusions with a total lesion length > 6 cm Occlusion length > 3.5 cm Calcification involving > 75% of the arterial wall circumference
     

“In a subcategory of TASC II D, lesions with long-segment severe stenosis of both the common and external iliac arteries, covered stents should be considered as the primary line of treatment.”1
-Piazza, et al

Additional patient benefits versus baseline

A systematic review and meta-analysis of two randomized controlled trials and four retrospective cohort studies compared outcomes with covered and uncovered stents when treating AIOD.8

The covered stent group demonstrated:

Covered stent graphic

Self Expanding or Balloon Expandable – when to use:

Self-expanding stent (SX)

    Shape memory alloys (e.g., nitinol).  Deployed via release of constraining mechanism.

Balloon-expanding stent (BX)

    Ductile metal alloys (e.g., stainless steel).  Deployed via angioplasty balloon inflation.
Attribute  
Radial strength / recoil resistance BX > SX
Diameter adjustment (taper / flare) BX > SX
Deployment accuracy BX > SX
Compression recovery SX > BX
Trackability / implanted conformability SX > BX
Length of device SX > BX
Device profile BX > SX

*As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS Heparin Surface.

  1. Piazza M, Squizzato F, Dall'Antonia A, et al.  Outcomes of self expanding PTFE covered stent versus bare metal stent for chronic iliac artery occlusion in matched cohorts using propensity score modelling.  European Journal of Vascular & Endovascular Surgery 2017;54(2):177-185.
  2. Mwipatayi BP, Sharma S, Daneshmand A, et al; COBEST co-investigators. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. Journal of Vascular Surgery 2016;64(1):83-94.e1.
  3. Sabri SS, Choudhri A, Orgera G, et al. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. Journal of Vascular & Interventional Radiology 2010;21(7):995-1003.
  4. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. Journal of Endovascular Therapy 2017;24(5):629-637.
  5. Squizzato F, Piazza M, Pulli R, et al; ILIACS Registry Group. Covered versus bare metal kissing stents for reconstruction of the aortic bifurcation in the ILIACS registry.  Journal of Vascular Surgery.  In press.
  6. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. Journal of Vascular Surgery 2015;61(3) Supplement:2S-41S.
  7. Laird JR, Zeller T, Holden A, et al; BOLSTER Investigators.  Balloon-expandable vascular covered stent in the treatment of iliac artery occlusive disease: 9-month results from the BOLSTER Multicenter Study.  Journal of Vascular & Interventional Radiology 2019;30(6):836-844.e1.
  8. Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA.  Covered vs uncovered stents for aortoiliac and femoropopliteal arterial disease: a systematic review and meta-analysis.  Journal of Endovascular Therapy 2016;23(3):442-452.

eIFU Symbol

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.